The Peter Attia Drive cover image

#75 - David Light: Zantac recall due to cancer concerns – what you need to know

The Peter Attia Drive

00:00

Cancer Risks and Zantac: Unraveling the Evidence

This chapter examines the critical differences between in vitro and in vivo cancer research, focusing on the implications of medications like Valsartan, losartan, and Zantac on human health. It discusses the presence of NDMA in Zantac, exploring its carcinogenic potential and the statistical challenges in gauging risk through epidemiological studies. The conversation highlights the need for comprehensive research to understand these risks and the alarming findings related to cancer-causing agents in commonly prescribed medications.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app